8-K: Elevai Labs Secures Exclusive Global License for Stem Cell Manufacturing Technology

Elevai Labs has obtained a worldwide exclusive license for INmune Bio's EMx technology, enabling in-house production of mesenchymal stromal cells for cosmetic products.

Summary

• Elevai Labs has entered into a license agreement with INmune Bio for the exclusive use of their EMx technology.
• This technology allows Elevai to manufacture human umbilical cord-derived mesenchymal stromal cells (hucMSCs) for use in topical cosmetic products.
• The agreement grants Elevai worldwide rights to develop, manufacture, and commercialize products using the EMx technology for a period of ten years.
• Elevai will make upfront payments, a final technology transfer fee, and a capped royalty on sales of licensed cosmetic products.
• Elevai will also supply INmune Bio with hUMSCs at a fixed percentage above production cost after successful manufacturing.
• The license agreement can be terminated for insolvency or material breach by either party.

Sentiment

Score: 8

Explanation: The document conveys a positive outlook due to the strategic partnership and potential for cost savings and improved product quality. The agreement is expected to enhance Elevai's competitive position.

Positives

• The agreement allows Elevai to control its manufacturing process, potentially leading to greater consistency and purity of stem cells.
• The EMx technology is expected to lower the cost of producing hucMSCs compared to market prices.
• The worldwide license provides Elevai with significant global market potential.
• The agreement aligns with Elevai's goal of vertical manufacturing integration.
• The agreement includes ethical sourcing and screening of umbilical cords.

Negatives

• Elevai is required to make upfront payments and pay royalties on sales of licensed products.
• The agreement includes a technology transfer fee payable two years after the effective date or upon completion of technology transfer, whichever is first.
• The agreement can be terminated for insolvency or material breach by either party.

Risks

• The success of the agreement depends on Elevai's ability to successfully implement the EMx technology.
• There is a risk of delays or issues in the technology transfer process.
• The agreement could be terminated if either party becomes insolvent or breaches the terms.
• The agreement includes a royalty payment on sales of licensed products, which could impact profitability.
• There is a risk that the cost savings from using the EMx technology may not be as significant as expected.

Future Outlook

Elevai expects the EMx technology to provide the ability to manufacture cGMP grade hucMSCs for its future topical cosmetic product development and manufacturing needs, at a lower cost than purchasing them at market, enhancing its competitive position for long-term success. The company also aims to expand its product portfolio and make a significant impact in the market.

Management Comments

• Jordan R. Plews, PhD, CEO of Elevai Labs, Inc. stated: partnering with INmune Bio, Inc. aligns perfectly with our mission to pioneer innovative stem cell exosome products.
• Jordan R. Plews, PhD, CEO of Elevai Labs, Inc. stated: Their understanding of efficient human stem cell isolation and large-scale manufacturing provides us with a remarkable opportunity to expand our manufacturing capabilities, expand our product portfolio, and make a significant impact in the market.

Industry Context

This agreement reflects a growing trend in the medical aesthetics industry towards vertical integration and in-house manufacturing to control costs and quality. It also highlights the increasing interest in stem cell-based products for skincare applications.

Comparison to Industry Standards

• Many companies in the medical aesthetics space rely on third-party manufacturers for key ingredients like stem cells, making Elevai's move towards in-house production a potential competitive advantage.
• The agreement with INmune Bio, a company with expertise in stem cell technology, positions Elevai to potentially achieve higher quality and more consistent product output.
• Other companies in the space, such as those focused on regenerative medicine, are also exploring in-house manufacturing of stem cell products, but Elevai's focus on topical cosmetic applications is a unique approach.
• The specific terms of the agreement, including the royalty structure and technology transfer fees, are not directly comparable to other publicly disclosed agreements, but the general trend is towards companies seeking greater control over their supply chain.

Stakeholder Impact

• Shareholders may view this agreement positively due to the potential for increased profitability and market share.
• Employees may benefit from the company's growth and expansion.
• Customers may benefit from higher quality and more consistent products.
• Suppliers may see changes in their relationship with Elevai as the company moves towards in-house manufacturing.
• Creditors may view this agreement as a positive step for the company's long-term financial health.

Next Steps

• Elevai will begin the technology transfer process to implement the EMx technology.
• Elevai will start manufacturing hucMSCs for use in its topical cosmetic products.
• Elevai will work towards expanding its product portfolio using the new technology.
• Elevai will provide annual reports to INmune Bio disclosing sales and royalty payments.

Key Dates

Keywords

stem cells, mesenchymal stromal cells, hucMSCs, EMx technology, licensing agreement, cGMP, cosmetics, manufacturing, INmune Bio, Elevai Labs